Kovaltry

Octocog alfa, the active ingredient in Kovaltry, is a recombinant factor VIII presented as a lyophilized powder for solution for injection for intravenous use. It replaces deficient factor VIII to treat and prevent bleeding in patients with hemophilia A, a hereditary clotting disorder.

GNH USA supplies Kovaltry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring product quality, regulatory compliance and cold‑chain logistics for biologic injectables. The company follows stringent Good Distribution Practice standards and provides technical support for product reconstitution and administration.

Kovaltry is a recombinant factor VIII used in the management of hemophilia A, a disorder of the intrinsic clotting pathway.

- Hemophilia A prophylaxis: provides regular factor VIII replacement to maintain trough levels and reduce spontaneous bleeding. - On‑demand treatment of bleeding episodes in Hemophilia A: delivers factor VIII to stop active bleeds. - Surgical prophylaxis in Hemophilia A: supplies factor VIII before and after surgery to prevent peri‑operative bleeding.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the infusion site. - Headache: transient, often resolves without intervention. - Fever: low‑grade temperature elevation post‑infusion. - Arthralgia: joint pain that may accompany bleeding episodes. - Nausea: occasional gastrointestinal upset. - Fatigue: generalized tiredness after treatment.

Serious or Rare Side Effects: - Inhibitor development: formation of neutralizing antibodies against factor VIII. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: clot formation in veins or arteries. - Severe hypersensitivity: rash, swelling, or respiratory distress. - Hemolysis: breakdown of red blood cells in rare cases.

Before using Kovaltry, consider the following precautions: - Bleeding risk assessment: evaluate baseline factor levels and recent bleed history. - Inhibitor monitoring: test regularly for anti‑factor VIII antibodies. - Allergy history: assess prior reactions to recombinant proteins or excipients. - Surgery planning: coordinate dosing schedule with surgical team to ensure adequate hemostasis. - Pregnancy and lactation: use only if potential benefits outweigh uncertain risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kovaltry may interact with other medicines as follows:

Major Interactions (Avoid): - Concurrent bypassing agents (e.g., activated prothrombin complex concentrates): may increase thrombotic risk. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): may counteract factor VIII efficacy.

Moderate Interactions (Monitor Closely): - Immunosuppressants: could affect inhibitor development. - Live vaccines: immune response may be altered. - Other plasma‑derived factor products: may increase immunogenicity.